enfortumab vedotin and pembrolizumab (EV/P)

DRUG2 trials

Sponsors

Guliz Ozgun, University of Florida

Conditions

Advanced Bladder CancerUrothelial Carcinoma (UC)

Phase 2

Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma

Not yet recruitingNCT07643519

University of FloridaUrothelial Carcinoma (UC)

Start: 2026-12-01End: 2030-10-01Target: 39Updated: 2026-09-14

Phase 3

The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer

Not yet recruitingNCT07346053

Guliz OzgunAdvanced Bladder Cancer

Start: 2026-05-01End: 2032-12-01Target: 224Updated: 2026-01-16